Drug Identification System

PillID

← Drug Encyclopedia 🌙

Uses & FDA Indications

Semaglutide is approved under different brand names for different indications. Ozempic and Rybelsus are approved for diabetes; Wegovy is approved for weight management. The underlying compound is the same.

FDA-Approved Uses

• Type 2 diabetes mellitus — adjunct to diet and exercise in adults (Ozempic, Rybelsus)
• Cardiovascular risk reduction — reduce risk of major adverse cardiovascular events (heart attack, stroke, cardiovascular death) in adults with type 2 diabetes and established cardiovascular disease (Ozempic — SUSTAIN-6 and SELECT trial data)
• Chronic weight management — long-term weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity, adjunct to diet and physical activity (Wegovy)
• Weight management in adolescents — Wegovy approved for chronic weight management in adolescents aged 12 and older with obesity
• Cardiovascular risk reduction in obesity — reduce risk of serious cardiovascular events in overweight/obese adults with established cardiovascular disease, without requiring type 2 diabetes (Wegovy — SELECT trial)

How It Works

Semaglutide is a synthetic analog of human GLP-1, structurally modified with a fatty acid chain and albumin-binding element that slows its degradation and extends its half-life to approximately one week — enabling once-weekly injection. GLP-1 receptors are expressed throughout the body, and semaglutide activates all of them.

In the pancreas, GLP-1 receptor activation stimulates glucose-dependent insulin secretion (insulin is released only when blood glucose is elevated, lowering hypoglycemia risk) and suppresses glucagon. In the stomach, it delays gastric emptying, slowing the absorption of nutrients and prolonging satiety after meals. In the brain — particularly in the hypothalamus and brainstem — it activates satiety centers, reduces appetite, diminishes food cravings, and changes hedonic responses to food. This central appetite suppression is the primary driver of the substantial weight loss seen with Wegovy.

The cardiovascular benefits appear to derive from multiple mechanisms: reduced atherosclerosis progression (possibly via anti-inflammatory effects in arterial walls), blood pressure reduction, and improvements in lipids. These effects occur independently of glucose lowering and weight loss.

Side Effects

Common

• Nausea — most common; typically most severe when starting or after dose escalations; usually improves over time
• Vomiting and diarrhea
• Constipation
• Abdominal pain and bloating
• Decreased appetite and early satiety
• Fatigue
• Injection site reactions (redness, swelling)
• Headache and dizziness

Serious

• Pancreatitis — acute pancreatitis, including fatal cases; discontinue if suspected
• Thyroid C-cell tumors — rodent studies showed dose-dependent thyroid tumors; human relevance uncertain but basis of black-box warning; contraindicated in patients with personal or family history of medullary thyroid carcinoma (MTC) or MEN2
• Gallbladder disease — increased rates of gallstones and cholecystitis; weight loss accelerates gallstone formation
• Hypoglycemia — primarily when combined with insulin or sulfonylureas; semaglutide alone has very low hypoglycemia risk
• Acute kidney injury — secondary to dehydration from GI side effects
• Gastroparesis and severe GI obstruction — delayed gastric emptying can become clinically problematic, particularly relevant for colonoscopy prep or anesthesia
• Diabetic retinopathy complications — rapid improvement in blood sugar can transiently worsen retinopathy in patients with pre-existing disease

Drug Interactions

Drug / Class	Interaction	Clinical Significance
Insulin and sulfonylureas (glipizide, glyburide)	Additive glucose-lowering effect; significantly increased hypoglycemia risk with combination	High — reduce insulin or sulfonylurea dose when adding semaglutide; monitor blood glucose closely
Oral medications (all)	Delayed gastric emptying reduces absorption rate and peak concentration of orally administered drugs; may affect medications requiring rapid absorption or with narrow therapeutic windows	Moderate — administer time-sensitive medications (e.g., levothyroxine, warfarin) consistently relative to semaglutide; monitor levels
Oral contraceptives	Delayed gastric emptying may reduce peak contraceptive hormone concentrations; overall exposure (AUC) effect is minimal but there is theoretical concern	Low–Moderate — take oral contraceptives at least 1 hour before or 4–6 hours after oral semaglutide (Rybelsus)
Warfarin	Delayed GI absorption and changes in food intake may affect INR; monitor closely when semaglutide is initiated	Moderate — check INR more frequently when starting or adjusting semaglutide
SGLT2 inhibitors (empagliflozin, dapagliflozin)	Additive glucose lowering; both classes have independent cardiovascular benefits — combination is increasingly used	Low — generally safe and complementary; monitor glucose and blood pressure
Metformin	Additive glucose lowering; no significant pharmacokinetic interaction; commonly combined as first-line combination in T2DM	Low — well-tolerated combination; monitor GI side effects as both can cause nausea
Alcohol	Alcohol increases risk of pancreatitis and may amplify hypoglycemia risk if combined with insulin or sulfonylureas	Moderate — advise limiting alcohol; abstain with history of pancreatitis

Warnings & Contraindications

Key Precautions

• Pancreatitis history: Use with caution; discontinue immediately if acute pancreatitis is suspected
• Retinopathy: Monitor patients with established diabetic retinopathy when initiating or escalating semaglutide due to risk of transient worsening
• Pre-operative considerations: Delayed gastric emptying increases aspiration risk under anesthesia; many anesthesiologists recommend stopping weekly semaglutide 1 week before elective procedures; discuss with your surgical and anesthesia team
• Gallbladder: Report symptoms of gallstones (right upper quadrant pain, especially after fatty meals)
• Heart rate: Semaglutide increases resting heart rate by approximately 2–4 beats per minute; monitor in patients with tachyarrhythmias

Frequently Asked Questions

What is the difference between Ozempic and Wegovy?

Ozempic and Wegovy both contain semaglutide — the same active molecule. The difference lies in their approved indications and dose ranges. Ozempic is approved for type 2 diabetes and cardiovascular risk reduction in diabetic patients, and is used in the lower part of the dose range. Wegovy is approved for chronic weight management in people with obesity or overweight with comorbidities, and uses a higher maximum dose to achieve greater weight loss. Rybelsus is an oral form of semaglutide approved for type 2 diabetes only.

How much weight can someone lose on semaglutide?

In the STEP clinical trials for Wegovy, participants lost an average of about 15% of their body weight over approximately 68 weeks, with about a third of participants losing 20% or more. This level of pharmacological weight loss is unprecedented compared to previous anti-obesity medications. Results vary significantly based on adherence, lifestyle factors, and individual biology. Weight regain after stopping semaglutide is common, suggesting that long-term or indefinite treatment may be necessary to maintain benefits.

Why is semaglutide contraindicated in pregnancy?

Animal studies showed fetal harm at exposures similar to those used in humans, including structural malformations and reduced fetal growth. Because semaglutide has a half-life of approximately one week, it takes several weeks to fully clear the body. Guidelines recommend stopping semaglutide at least 2 months before attempting to conceive to ensure the drug has fully cleared before early fetal development. If pregnancy occurs while on semaglutide, the drug should be stopped immediately and an obstetric consultation sought.

Does semaglutide need to be given forever?

For most people, the benefits of semaglutide on blood sugar, weight, and cardiovascular risk require ongoing treatment. When semaglutide is stopped, blood glucose tends to rise and most of the lost weight returns — often within months. This is similar to taking a blood pressure medication: the underlying physiology that the drug is compensating for (insulin resistance, impaired satiety signaling) does not go away. Many researchers view obesity as a chronic condition requiring long-term pharmacological management, similar to hypertension or diabetes.

→ Diabetes Medication Side Effects Guide → Type 2 Diabetes Medications Guide